Jesus F San-Miguel
Overview
Explore the profile of Jesus F San-Miguel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
4485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puig N, Agullo C, Contreras T, Cedena M, Martinez-Lopez J, Oriol A, et al.
Blood
. 2024 Sep;
144(23):2432-2438.
PMID: 39293025
Quantitative immunoprecipitation mass spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in complete response, and could be considered suitable for measurable residual disease...
2.
Mateos M, Martinez-Lopez J, Otero P, Gonzalez-Calle V, Gonzalez M, Oriol A, et al.
J Clin Oncol
. 2024 Jul;
42(27):3247-3256.
PMID: 39038268
Purpose: Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for...
3.
Martin-Sanchez E, Tamariz-Amador L, Guerrero C, Zherniakova A, Zabaleta A, Maia C, et al.
Blood Cancer J
. 2024 Jul;
14(1):111.
PMID: 38987557
Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood...
4.
Gonzalez-Calle V, Rodriguez-Otero P, Sureda A, de Arriba F, Reinoso M, Ribas P, et al.
Haematologica
. 2024 Feb;
109(7):2219-2228.
PMID: 38356463
The treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In...
5.
Martin T, Moreau P, Usmani S, Garfall A, Mateos M, San-Miguel J, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Dec;
24(3):194-202.
PMID: 38052709
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and...
6.
Guerrero C, Puig N, Cedena M, Calasanz M, Gutierrez N, Fernandez M, et al.
Blood
. 2023 Dec;
143(7):597-603.
PMID: 38048552
The role of measurable residual disease (MRD) negativity as a biomarker to stop treatment is being investigated in transplant-eligible patients with multiple myeloma (MM). Thus, it is important to identify...
7.
8.
Rodriguez-Otero P, Tamariz L, San-Miguel J
Lancet Haematol
. 2023 Oct;
10(10):e786-e787.
PMID: 37793761
No abstract available.
9.
Botta C, Perez C, Larrayoz M, Puig N, Cedena M, Termini R, et al.
Nat Commun
. 2023 Sep;
14(1):5825.
PMID: 37730678
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of...
10.
Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki C, Martin N, et al.
Blood Cancer Discov
. 2023 Jul;
4(5):365-373.
PMID: 37486974
Significance: This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic...